REG - ValiRx PLC - Director/PDMR Shareholding
RNS Number : 5433VValiRx PLC07 August 2020VALIRX PLC
("ValiRx", the "Company" or the "Group")
Director Dealing
London, UK 7 August 2020: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company announces the following dealing in the ordinary shares of the Company made by a Director.
On 7 August 2020, the Company was informed that Dr Kevin Cox, Non-executive Chairman of the Company, acquired 117,000 ValiRx ordinary shares at an average price of 8.2 pence per share on 7 August 2020, representing approximately 0.22% of the Company's issued ordinary share capital. Following this acquisition, Dr Cox now holds an interest in 250,333 ValiRx ordinary shares, representing approximately 0.46% of the Company's issued ordinary share capital.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information please contact:
ValiRx plc
Tel: +44 (0) 20 7073 2628
Suzanne Dilly
Suzanne.Dilly@valirx.com
Cairn Financial Advisers LLP(Nominated Adviser)
Liam Murray / Jo Turner / Ludovico Lazzaretti
Tel: +44 (0) 20 7213 0880
Peterhouse Capital Limited (Sole Broker)
Duncan Vasey / Lucy Williams / Eran Zucker
Tel: +44 (0) 20 7469 0930
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1
Details of the person discharging managerial responsibilities/person closely associated
a.
Name
Dr Kevin Cox
2
Reason for notification
a.
Position/Status
Non-executive Chairman
b.
Initial notification/
Amendment
Initial
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.
Name
ValiRx PLC
b.
LEI
213800VQKB9SJCQDET40
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.
Description of the financial instrument, type of instrument
Identification CodeOrdinary Shares
ISIN: GB00BLH13C52
b.
Nature of the transaction
On market Purchase
c.
Price(s) and volume(s)
Price(s)
Volume(s)
8.2 pence
117,000
d.
Aggregated information
- Aggregated Volume
- Price
N/A
e.
Date of the transaction
07/08/2020
f.
Place of the transaction
London, UK
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDDSHBXGDIIBGDGGR
Recent news on ValiRx
See all newsREG - ValiRx PLC - Directorate Changes
AnnouncementREG - ValiRx PLC - Evaluation Agreement with Imperial College London
AnnouncementREG - ValiRx PLC - Board Re-structuring and update on requisition
AnnouncementREG - ValiRx PLC - Shareholder Requisition Notice
AnnouncementREG - ValiRx PLC - Proposed Appointment of Non-Executive Director
Announcement